A Comprehensive Cost Variation Analysis of Drugs Used in the Management of Type-2 Diabetes Mellitus Across India

Abinish  D.G

doi:10.18502/jppm.v10i3.20251

Abinish D.G Department of Clinical Pharmacy, Government Medical College and Hospital, Nagapattinam, Tamil Nadu, India

DOI: https://doi.org/10.18502/jppm.v10i3.20251

Keywords: Cost variation analysis, Antidiabetic agents, Drug Price Control Order, Diabetes Mellitus

Abstract

Background: This study aims to examine the cost variations of oralantidiabetic agents in India, highlighting the financial barriers that may impactpatient adherence and treatment efficacy.

Methods: This analytical study was performed by analysing the prices of 18 oralantidiabetic drugs with 42 formulations. Data was collected from the NationalPharmaceutical Pricing Authority (NPPA) platform, focusing on single-drug tabletformulations. Price variations were assessed using cost ratios and percentagecost variations. Compliance with the Drug Price Control Order (DPCO) ceilingprices were also analysed.

Results: The study revealed significant price variations among different brandsof the same drug, with voglibose 0.3 mg exhibiting the highest cost ratio(1:139.92) and percentage variation (13892.30%). Additionally, a notableproportion of brands exceeded the DPCO ceiling prices, particularly metformin1000 mg, where 9 out of 15 brands were non-compliant to the ceiling price.

Conclusion: Despite the presence of a regulatory authority, substantial pricevariability among oral antidiabetic agents persists in India, potentially affectingpatient adherence and health outcomes. The violations of DPCO pricingregulations indicate a need for stricter enforcement and expansion of pricecontrols to ensure the affordability of essential medications and improve overallpatient care.